28 agosto 2014
A new clinical trial of a drug was shown to safely reduce the viral load and clinical illness of healthy adult volunteers intranasally infected with respiratory syncytial virus (RSV). RSV is the most common cause of lower respiratory tract infections in young children in the United States and worldwide. It hospitalizes 125,000 children in the United States each year, and was the cause for 1.5 million outpatient visits.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/yXF6vLiSM50/140828170015.htm
